Study of Antenatal Magnesium Sulphate to Prevent Cerebral Palsy in Women at High Risk of Preterm Birth Between 32 and 35 Weeks

What this Trial Is About

Researchers are evaluating whether giving magnesium sulphate to pregnant women at high risk of preterm birth can reduce the chance of cerebral palsy in their infants. This trial focuses on women between 32 and 35 weeks of pregnancy who are expected to deliver within 24 hours. The study also aims to assess the safety of magnesium sulphate for both mothers and newborns by comparing it to a placebo. Participants will be randomly assigned to receive either intravenous magnesium sulphate or a placebo. The magnesium sulphate is given as a 4 gram loading dose over 20 minutes, followed by a maintenance infusion of 1 gram per hour until delivery or for up to 24 hours. The placebo group receives an intravenous sodium chloride solution following the same schedule. Both groups will receive standard obstetric and neonatal care throughout the study. During the study, mothers will be monitored for side effects while receiving the infusion. Newborns will have routine assessments and cranial ultrasound screenings when needed. After discharge, infants will be followed up with neurodevelopmental evaluations to check for cerebral palsy. The main outcome measured is the combined rate of death or cerebral palsy at 6 months corrected age. The study will also track maternal side effects up to 48 hours after infusion and neonatal health up to 4 weeks after birth.

Antenatal Magnesium Sulphate in High-Risk Preterm Patients